All-trans-retinoic acid induces CD52 expression in acute promyelocytic leukemia

Shi Wu Li, Dongqi Tang, Kim P. Ahrens, Jin-Xiong She, Raul C. Braylan, Lijun Yang

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

It is well known that all-trans-retinoic acid (ATRA) can induce myeloid cell differentiation in acute promyelocytic leukemia (APL) cells. In this study, we found that ATRA treatment of the APL cell line NB4 induced the expression of CD52, both at transcriptional and translational levels. CD52 is a 21- to 28-kDa nonmodulating cell surface glycosylphosphatidylinositol-linked glycoprotein expressed on lymphocytes and monocytes, but not in human myeloid cells. The ATRA-dependent induction of CD52 expression was not observed in non-promyelocytic leukemia cell lines such as K562, U937, and HL-60, suggesting that induction of CD52 by ATRA may be specific to leukemic cells that express promyelocytic leukemia- retinoic acid receptor α (PML-RARα) or are at the promyelocytic stage of myeloid development. Antibodies against CD52 are used therapeutically against lymphocytes in certain leukemias and in patients undergoing transplantation. An ATRA-induced high level of CD52 expression might potentially serve as a novel therapeutic target in treatment of APL.

Original languageEnglish (US)
Pages (from-to)1977-1980
Number of pages4
JournalBlood
Volume101
Issue number5
DOIs
StatePublished - Mar 1 2003
Externally publishedYes

Fingerprint

Acute Promyelocytic Leukemia
Tretinoin
Leukemia
Lymphocytes
Myeloid Cells
Cells
Cell Line
Glycosylphosphatidylinositols
Retinoic Acid Receptors
Monocytes
Cell Differentiation
Glycoproteins
Therapeutics
Transplantation
Antibodies

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Li, S. W., Tang, D., Ahrens, K. P., She, J-X., Braylan, R. C., & Yang, L. (2003). All-trans-retinoic acid induces CD52 expression in acute promyelocytic leukemia. Blood, 101(5), 1977-1980. https://doi.org/10.1182/blood-2002-05-1426

All-trans-retinoic acid induces CD52 expression in acute promyelocytic leukemia. / Li, Shi Wu; Tang, Dongqi; Ahrens, Kim P.; She, Jin-Xiong; Braylan, Raul C.; Yang, Lijun.

In: Blood, Vol. 101, No. 5, 01.03.2003, p. 1977-1980.

Research output: Contribution to journalArticle

Li, SW, Tang, D, Ahrens, KP, She, J-X, Braylan, RC & Yang, L 2003, 'All-trans-retinoic acid induces CD52 expression in acute promyelocytic leukemia', Blood, vol. 101, no. 5, pp. 1977-1980. https://doi.org/10.1182/blood-2002-05-1426
Li, Shi Wu ; Tang, Dongqi ; Ahrens, Kim P. ; She, Jin-Xiong ; Braylan, Raul C. ; Yang, Lijun. / All-trans-retinoic acid induces CD52 expression in acute promyelocytic leukemia. In: Blood. 2003 ; Vol. 101, No. 5. pp. 1977-1980.
@article{bf8c194b49ca4c1ea39ad53ab94ad65e,
title = "All-trans-retinoic acid induces CD52 expression in acute promyelocytic leukemia",
abstract = "It is well known that all-trans-retinoic acid (ATRA) can induce myeloid cell differentiation in acute promyelocytic leukemia (APL) cells. In this study, we found that ATRA treatment of the APL cell line NB4 induced the expression of CD52, both at transcriptional and translational levels. CD52 is a 21- to 28-kDa nonmodulating cell surface glycosylphosphatidylinositol-linked glycoprotein expressed on lymphocytes and monocytes, but not in human myeloid cells. The ATRA-dependent induction of CD52 expression was not observed in non-promyelocytic leukemia cell lines such as K562, U937, and HL-60, suggesting that induction of CD52 by ATRA may be specific to leukemic cells that express promyelocytic leukemia- retinoic acid receptor α (PML-RARα) or are at the promyelocytic stage of myeloid development. Antibodies against CD52 are used therapeutically against lymphocytes in certain leukemias and in patients undergoing transplantation. An ATRA-induced high level of CD52 expression might potentially serve as a novel therapeutic target in treatment of APL.",
author = "Li, {Shi Wu} and Dongqi Tang and Ahrens, {Kim P.} and Jin-Xiong She and Braylan, {Raul C.} and Lijun Yang",
year = "2003",
month = "3",
day = "1",
doi = "10.1182/blood-2002-05-1426",
language = "English (US)",
volume = "101",
pages = "1977--1980",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "5",

}

TY - JOUR

T1 - All-trans-retinoic acid induces CD52 expression in acute promyelocytic leukemia

AU - Li, Shi Wu

AU - Tang, Dongqi

AU - Ahrens, Kim P.

AU - She, Jin-Xiong

AU - Braylan, Raul C.

AU - Yang, Lijun

PY - 2003/3/1

Y1 - 2003/3/1

N2 - It is well known that all-trans-retinoic acid (ATRA) can induce myeloid cell differentiation in acute promyelocytic leukemia (APL) cells. In this study, we found that ATRA treatment of the APL cell line NB4 induced the expression of CD52, both at transcriptional and translational levels. CD52 is a 21- to 28-kDa nonmodulating cell surface glycosylphosphatidylinositol-linked glycoprotein expressed on lymphocytes and monocytes, but not in human myeloid cells. The ATRA-dependent induction of CD52 expression was not observed in non-promyelocytic leukemia cell lines such as K562, U937, and HL-60, suggesting that induction of CD52 by ATRA may be specific to leukemic cells that express promyelocytic leukemia- retinoic acid receptor α (PML-RARα) or are at the promyelocytic stage of myeloid development. Antibodies against CD52 are used therapeutically against lymphocytes in certain leukemias and in patients undergoing transplantation. An ATRA-induced high level of CD52 expression might potentially serve as a novel therapeutic target in treatment of APL.

AB - It is well known that all-trans-retinoic acid (ATRA) can induce myeloid cell differentiation in acute promyelocytic leukemia (APL) cells. In this study, we found that ATRA treatment of the APL cell line NB4 induced the expression of CD52, both at transcriptional and translational levels. CD52 is a 21- to 28-kDa nonmodulating cell surface glycosylphosphatidylinositol-linked glycoprotein expressed on lymphocytes and monocytes, but not in human myeloid cells. The ATRA-dependent induction of CD52 expression was not observed in non-promyelocytic leukemia cell lines such as K562, U937, and HL-60, suggesting that induction of CD52 by ATRA may be specific to leukemic cells that express promyelocytic leukemia- retinoic acid receptor α (PML-RARα) or are at the promyelocytic stage of myeloid development. Antibodies against CD52 are used therapeutically against lymphocytes in certain leukemias and in patients undergoing transplantation. An ATRA-induced high level of CD52 expression might potentially serve as a novel therapeutic target in treatment of APL.

UR - http://www.scopus.com/inward/record.url?scp=0037369285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037369285&partnerID=8YFLogxK

U2 - 10.1182/blood-2002-05-1426

DO - 10.1182/blood-2002-05-1426

M3 - Article

VL - 101

SP - 1977

EP - 1980

JO - Blood

JF - Blood

SN - 0006-4971

IS - 5

ER -